Company news

Cocrystal Pharma, Inc. news in 2023

Cocrystal Pharma, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

December 5, 2023

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

November 28, 2023

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

November 26, 2023

Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

November 12, 2023

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

November 8, 2023

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

October 30, 2023

Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus

September 27, 2023

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

September 4, 2023

Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

August 13, 2023

Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead

August 7, 2023

Cocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988

May 30, 2023

Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

May 14, 2023

Cocrystal Pharma Presents New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference

May 3, 2023

Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors

April 23, 2023

Cocrystal Pharma to Present New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference

April 17, 2023

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

April 9, 2023

Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs

March 28, 2023

Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023

March 21, 2023

Cocrystal Pharma Announces Participation in Virtual Investor Events

January 25, 2023

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

January 22, 2023

Decks in 2023